---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060693"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T10:41:16.624994+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PepGen Q3 2023 net loss $23.3M; cash $129.5M; FDA clears FREEDOM-DM1 study in US

## Summary
- Net loss of $23.3M for Q3 2023, vs $18.6M in Q3 2022; R&D expenses $20.5M.
- Cash and cash equivalents $129.5M as of Sept 30, 2023; runway expected into 2025.
- FDA lifted clinical hold on FREEDOM-DM1 Phase 1 study; target doses 5, 10, 20 mg/kg.
- FDA granted Orphan Drug Designation to PGN-EDODM1 for myotonic dystrophy type 1.
- Anticipates proof-of-concept data from CONNECT1-EDO51 study in mid-2024.

## SEC filing metadata
- accession: 0000950170-23-060693
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017023060693/0000950170-23-060693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017023060693/pepg-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060693
- JSON: https://secwatch.observer/filing/0000950170-23-060693.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060693.txt

## Key facts
- Earnings Releases
  PepGen Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $23.3 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net loss was $23.3 million
  - Result: reported results
  source text: PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2023 and highlighted recent corporate developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835597/000095017023060693/0000950170-23-060693-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.